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Summary BW12C (5-[2-formyl-3-hydroxypenoxyl] pentanoic acid) is an agent which stabilises oxyhaemo-
globin and thus reduces oxygen delivery to tissues. It is of interest as a possible potentiator of bioreductive
agents and/or hyperthermia. The increases in radiobiological hypoxic fraction of RIF-I and KHT tumours
30 min after 70 mg kg BW12C i.v. were measured and shown to be similar; factors (±2 s.e.) ranged from
3.87 (2.84-5.29) to 5.92 (1.92-18.2) despite the large variation in initial hypoxic fraction, from 0.30
(0.18-0.50) % for RIF-1 intramuscularly in the leg to 16.3 (14.7-18.1) % for subcutaneous KHT flank
tumours. Thermosensitivity of intramuscular KHT leg tumours was not enhanced by 70 mgkg-' BW12C
30 min before heating at 43C, 43.5C or 44C, assayed by regrowth delay. The effect of 70mg kg-' BW12C
on relative tissue perfusion (RTP), assayed by 86Rb extraction, was measured from 0.5 h to 6 h after treatment.
After I h RTP (±2 s.e.) in RIF-l tumours was reduced to 84±5.7% and 68±9.6% of control in leg and flank
tumours respectively, and to 86± 6.4% in leg muscle while flank skin RTP was unaltered
at 109±8.6%. There were substantial increases in kidney (149±10.7%) spleen (173±22.1%) and lung
(128± 10.4%) at 1 h but in liver there was a decrease at 2 h to 85 ± 8.4%. Dose response studies showed that
the threshold dose for reduction of tumour RTP is between 55 and 70 mg kg-', but perturbations in normal
tissue RTP occur at lower doses, e.g. 40mg kg-' for spleen. BW12C had minimal effects on renal function
measured by 5'CrEDTA clearance. The data as a whole indicate that reduction in tumour perfusion is likely to
be an important determinant in the increase in tumour hypoxia induced by BW12C.
Considerable effort has recently been invested in the explora-
tion of possible techniques for the manipulation of tissue
oxygenation in cancer therapy. While increased oxygenation
would be expected to improve response to radiotherapy in
circumstances where its efficacy is limited by the presence of
hypoxic cells, decreased oxygenation also has important
potential applications. These lie primarily in two fields: in the
activation or potentiation of bioreductive agents and in the
potentiation of hyperthermic damage. Bioreductive agents
are specifically designed to be activated or dramatically
potentiated in a reducing environment, such as is thought to
exist in many solid tumours (Sartorelli, 1988). Mitomycin C
(Kennedy, 1987), RSU 1069 (Stratford et al., 1986) and SR
4233 (Zeman et al., 1986) are currently the leading drugs of
different subclasses of this type of agent and development in
this area is very active. Hyperthermic damage has long been
known to be enhanced by hypoxia and consequent pH
changes in vitro (Overgaard & Bichel, 1977; Gerweck et al.,
1979), and recent in vivo data show that acute hypoxia
associated with reduced blood flow can potentiate thermal
damage in murine tumours (Horsman et al., 1989; Honess et
al., 1991a).
BW12C (5-[2-formyl-3-hydroxyphenoxy] pentanoic acid) is
a drug which binds to and stabilises oxyhaemoglobin, thus
causing a left shift in the oxygen saturation curve. This has
been demonstrated in vitro for human blood (Beddell et al.,
1984) and in vivo in human volunteers (Fitzharris et al.,
1985), sickle cell patients (Keidan et al., 1986) cancer patients
(Ramsay et al., 1991), pigs (van den Aardweg et al., 1991)
and mice (Adams et al., 1986; Honess et al., 1991b). For any
partial pressure of oxygen the left-shifted haemoglobin
releases less oxygen to the tissues and in consequence
hypoxia is induced. This reduction in oxygen release will take
place in all tissues, but a tumour-selective element lies in the
fact that the oxygen tension in the tumour is thought to be
typically lower than elsewhere, hence a further reduction may
be sufficient to generate a reducing environment appropriate
for bioreduction or thermosensitisation. BW12C has pre-
viously been shown to protect both murine tumours (Adams
et al., 1986 and 1989, Honess et al., 1991b) and human
tumour xenografts (Cole & Robbins, 1989) from radiation, in
a manner consistent with an increase in hypoxic fraction. In
the Lewis lung tumour (Adams et al., 1986), KHT tumour
(Adams et al., 1989) and MAWI xenograft (Cole & Robbins,
1989), all grown subcutaneously, the effect was compatible
with the induction of complete hypoxia, but in RIF-1 intra-
muscular tumours the radioprotection was more modest
(Honess et al., 1991b). Preliminary blood flow studies sug-
gested that the increase in hypoxic fraction might. be at least
partially due to a reduction in tumour perfusion (Honess et
al., 1989). The thermosensitivity of the intramuscular RIF-I
tumour was shown not to be affected by the drug (Honess et
al., 1989), but the hypoxic fraction in this tumour is very low
(Brown et al., 1980) and it seemed possible that the degree of
hypoxia achieved was inadequate to enhance thermosensiti-
vity. In the light of these observations the aims of the present
study were:
(a) to measure the change in radiobiological hypoxic frac-
tion brought about by BW12C in two murine tumours,
each grown in two separate sites
(b) to investigate the effect of BW12C on the thermosen-
sitivity of the KHT tumour which is reported to have
a higher inherent hypoxic fraction than that of the
RIF-1 tumour (Moulder & Rockwell, 1984) and
(c) to conduct a more detailed study of the effect of
BW12C on the relative tissue perfusion of one tumour
in two sites and in a range of normal tissues.
Materials and methods
Animals and tumour models
Female C3H/Km mice 10-16 weeks old were used for this
study. The RIF-1 (Twentyman et al., 1980) and KHT (Kall-
man et al., 1967) tumours were used and were grown either
intramuscularly in the leg or intradermally (RIF-1) or sub-
cutaneously (KHT) in the flank. RIF-1 tumours were grown
from cells from culture and KHT tumours from cell suspen-
sions from disaggregated tumours. Tumours were treated at a
volume of 250-450mm3 unless otherwise specified; i.e. for
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RIF-1 tumours at 10-11 days after inoculation in the leg
and 14-15 days after inoculation in the flank and for KHT
tumours at 7-8 days after inoculation in the leg and 10-11
days after inoculation in the flank.
Drug
BW12C (5-[2-formyl-3-hydroxyphenoxy] pentanoic acid)
was kindly provided by Dr A.B.W. Nethersell, Wellcome
Research Laboratories (Beckenham, Kent) as a pale yellow
powder. It was prepared daily by dissolving in alkaline
solution (NaOH) then bringing back to pH 7.4 with HCI and
protecting from light. It was administered to mice intra-
venously (i.v.) via the tail vein at 70 mg kg-' given in a volume
of 5 ml kg-'.
Irradiation
This was carried out using a 250 kV X-ray machine (Pantak,
UK) at a dose rate of 67.4 cGy min '. Unanaesthetised mice
were placed in a subdivided, ventilated perspex box for treat-
ment. BW12C or PBS was given 30 min before the start of
irradiation and mice were put in the box immediately after
injection to allow acclimatisation to the box before treat-
ment. The time interval of 30 min between administration of
BW12C and the start of irradiation was selected since
previous work with the RIF-l tumour has shown that the
radioprotective effect of BW12C is maximal in this system
with this time interval (Honess et al., 1991b). Anoxic condi-
tions were achieved by killing the mice by enclosing the box
in another container and gassing with nitrogen for 15 min
before and during irradiation. These experiments were car-
ried out on mice bearing a single tumour in either the leg or
the flank.
Hyperthermia
This was administered to unanaesthetised mice as previously
described (Honess et al., 1991a). Briefly, the heating system
used is a combined computer-controlled radiofrequency and
waterbath device which allows uniform heating of a tumour-
bearing leg with temperature control to within ± 0.1°C of
target temperature (Walton et al., 1989). This apparatus is
designed specifically for the treatment of intramuscular
tumours in the leg and is not appropriate for the treatment
of flank tumours. BW12C was given 30 min before the start
of heating which was for 30 min. Unheated animals were
sham-heated by restraint in the customised jigs, with inser-
tion of dummy rectal and tumour thermocouples, for 30 min.
Assay oftumour response to radiotherapy or hyperthermia
Tumour response to radiotherapy was measured by clono-
genic cell survival as previously described for RIF-1 (Honess
& Bleehen, 1982) and for KHT (Honess et al., 1991a), assay-
ing survival immediately after irradiation. Experiments were
repeated at least once, except where specifically stated, and
data were pooled. Response of the KHT tumour to hyper-
thermia was measured by regrowth delay assay. The endpoint
was the time to reach 4 times treatment volume. Groups of
10-14 mice were used for each treatment group and geomet-
ric means and standard errors were calculated for each
group. Experiments were repeated at least once, and data
were pooled.
Calculation ofhypoxicfraction
The hypoxic fractions of RIF-I and KHT tumours in both
locations were calculated by the paired survival curve method
(Moulder & Rockwell, 1984) i.e. measuring the separation of
the survival curves on the hypoxic tail of the response curve
for air-breathing animals. In cases where the survival curve
for tumours in air-breathing animals did not become parallel
to the curve for hypoxic tumours, an estimate of hypoxic
fraction was made by calculating the separation of the curves
at the highest radiation dose used. This gives a minimum
value for hypoxic fraction (Moulder & Rockwell, 1984).
Measurement ofrelative tissueperfusion (RTP)
RTP is a measure of tissue blood flow as a proportion of
cardiac output. It was assayed by the 86Rb extraction method
developed by Sapirstein (1959) and used as previously des-
cribed (Honess & Bleehen, 1991). Activity trapped in the tail
was subtracted for each individual mouse, then the percen-
tage of circulating activity retained per gram of each tissue
examined was calculated. Ten to 12 mice were treated per
group and results are expressed as percentage of the mean
control value measured for each tissue. Where data for more
than one experiment were pooled, the values pooled were
percentages of mean control value, rather than absolute
values.
The tissues of interest included the RIF-l tumour, growing
intramuscularly in the leg and intradermally in the flank, and
the 'upstream' tissues for these tumour sites, namely muscle
and skin. In order to avoid contamination of normal tissue
by tumour in a manner compatible with rapid excision of all
tissues (i.e. within 90-120 s of killing the animal), muscle
and skin samples were taken from the contralateral leg and
flank. In these experiments mice carried a tumour in each
site, to enable comparison of the effects of BW12C on RTP
of tumours in different sites in the same animals. The other
tissues of interest were kidney, lung, liver and spleen. The
lung and kidney differ from the other organs assayed in that
they are relatively high flow tissues in comparison with the
others; control extraction values are around 8-9% and
20-25% injected 86Rb per gram respectively, in contrast with
values range from 1-3% injected 86Rb per gram for the other
tissues, including tumour. The high flow rates reflect the
'service' capacity of these organs, and only a small and
unmeasured proportion of the flow comprises their own
nutritive flow. Nonetheless, variable changes in extraction
rates are seen with different vasoactive agents, and such
changes probably reflect to a certain extent changes in car-
diac output. Since cardiac output cannot yet be measured in
unanaesthetised mice, these changes are valuable indicators
of the actions of a drug.
Measurement ofrenalfunction
The effect of BW12C on renal function was assayed by
monitoring clearance of intravenously injected 51CrEDTA as
previously described (Honess & Bleehen, 1991). Five mice
were used per time-point and plasma EDTA concentration
was measured at 5, 10, 30 and 60min after injection.
Data analysis
This was carried out on a Macintosh SE/30 computer. Means
and standard errors of these means were calculated using the
Statview program; unpaired, two-tailed t-tests were carried
out where appropriate using the Statworks program. Regres-
sion analysis of radiation dose-response curves and EDTA
plasma clearance curves, to measure slopes and intercepts
and their associated errors, was also carried out using the
Statworks program.
Results
Effect ofBW12C on tumour radiation response
Radiation dose response curves for RIF-1 and KHT tumours
grown in the leg or in the flank are presented in Figure 1 for
animals receiving PBS or 70mgkg-' BW12C 30min before
the start of radiation. BW12C had no effect on the survival
of unirradiated cells. Data are also presented for tumours in
animals killed by nitrogen asphyxiation, showing the radio-
sensitivity of anoxic cells. The parameters describing these
dose-response curves are presented in Table I. BW12CBW12C: HYPOXIA AND BLOOD FLOW 717
Table I Parameters ofradiation dose response curves for RIF-I and KHT tumours in nitrogen asphyxiated animals or in
air-breathing animals treated with PBS or 70mgkg-' BW12C 30 min before irradiation. Also presented are the calculated
values for the hypoxic fractions of the tumours, and the increase in hypoxic fraction due to BW12C
Tumour Dose range' Do (Gy) Hypoxicfraction Increase in HFby
and site Treatment (Gy) +2 s.e. n ± 2 s.e. (HF)%±2 s.e. BW12C ( 2s.e.)
RIF-1 leg PBS 6-22 2.03 (1.87-2.22) 4.06 (2.10-7.86) 0.30 (0.18-0.50)
RIF-1 leg Anoxia 10-26 4.36 (3.93-4.89) 4.16 (2.62-6.61) 100
RIF-1 leg BW12C 6-22 2.45 (2.18-2.80) 3.22 (1.41-7.34) 1.51 (0.81-2.83) 5.04 (2.29-11.3)
RIF-1 flank PBS 18-28 3.06 (2.36-4.34) 3.76 (0.40-35.4) 4.53 (1.96-10.4)
RIF-1 flank Anoxia 18-30 3.80 (2.89-5.56) 13.9 (1.82-107) 100
RIF-1 flank BW12C 18-28 3.44 (2.71-4.73) 7.94 (1.29-48.7) 26.8 (12.7-56.1) 5.92 (1.92-18.2)
KHT leg PBS 5-25 2.77 (2.70-2.85) 0.46 (0.39-0.54) 0.96 (0.80-1.14)
KHT leg Anoxia 5-25 4.01 (3.85-4.18) 3.00 (2.51-3.58) 100
KHT leg BW12C 10-25 2.81 (2.70-2.94) 1.58 (1.19-2.08) 3.71 (2.87-4.80) 3.87 (2.84-5.29)
KHT flank PBS 15-25 2.84 (2.73-2.95) 6.37 (4.84-8.39) 16.3 (14.7-18.1)
KHT flank Anoxia 15-25 3.23 (3.14-3.32) 13.3 (11.3-15.6) 100
KHT flank BW12C 20-25 3.15 (2.94-3.39) 11.2 (6.7-18.4) 69.0 (62.3-76.5) 4.24 (3.66-4.91)
'Dose range for estimation of parameters of response curves.
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Figure 1 The effects of 70mg kg-' BW12C given 30 min before the start of irradiation on the radiation response of the RIF-1
(upper panels) and KHT (lower panels) tumour growing in the leg (left panels) or in the flank (right panels). Animals were treated with PBS (@) or 70mg kg-' BW12C (0) 30 min before the start of irradiation. Anoxic tumours (A) were produced by nitrogen
asphyxiation. Values are geometric means of 6-9 estimations pooled from two or three separate experiments for each tumour type,
except for the KHT flank data which are for six separate estimates per point from the same experiment. Bars show±2 s.e. where
these exceed the size of the symbol. (Reproducibility was found to be rather better for the KHT than for the RIF-1 tumour.)
reduces radiosensitivity in both tumours, growing in either
the leg or the flank, in a manner compatible with an increase
in hypoxic fraction. The increases in hypoxic fraction have
been calculated and are presented in Table I. For RIF-I the
increases are by factors of 5.0 and 5.9 for leg and flank
tumours respectively, i.e. there is a very similar degree of
increase in hypoxia despite the 15-fold difference in hypoxic
fraction in the two sites (Table I). This similarity of increase
in hypoxic fraction is also observed for the KHT tumour
where the increases are by factors of 3.9 and 4.2 for leg and
flank tumours respectively, and the hypoxic fraction in the
flanks is 17-fold higher than in the leg tumours.
Effect ofBW12C on tumour thermosensitivity
The effect of 70 mg kg-' BW12C administered 30 min before
heating on the thermal response of the KHT tumour grown
in the leg was studied. Treatment was for 30 min at 43°C,
43.5°C or 44°C. The mean time for control tumours to reach
four times treatment volume was 2.2 ± 0.1 days (n = 72).
BW12C with sham heating had a very small effect, inducing
less than half a day of growth delay. Growth delay due to
heat alone was dose dependent, giving delays ( ± 2 s.e.) of
e.g. 0.45 ± 0.36 days for 43C, 2.2 ± 0.2 days for 43.5°C and
2.3 ± 1.1 days for 44°C. BW12C did not potentiate this
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effect. This is clear since the observed growth delay due to
combined BW12C and heat is essentially the same as that
predicted by the sum of the delays due to BW12C alone and
heat alone. Observed delay for combined treatment at 43C
was 0.95 ± 0.42 days, compared with a predicted value of
0.67 ± 0.44 days, and the corresponding delays for 43.5C
were 2.1 ± 0.1 days (observed) and 2.2 ± 0.2 days (predicted),
and for 44°C were 2.8 ± 0.7 days (observed) and 2.6 ± 1.1
days (predicted).
Effect ofBW12C on relative tissueperfusion
Reproducibility between 86Rb extraction experiments in terms
of the control values for percentage of injected activity per
gram of tissue was good. For example, values (± 2 s.e.) for
the experiments presented below were: leg tumour, 2.78 ±
0.28% and 2.82 ± 0.26%; flank tumour, 1.77 + 0.21% and
2.14 ± 0.91%; skin, 1.07 ± 0.07%, 1.10 ± 0.12% and 1.03 +
0.13%; muscle 2.98 ± 0.25%, 3.09 ± 0.29% and 2.95 ± 0.30%;
kidney, 21.33 ± 2.47%, 21.10 ± 2.08% and 21.63 ± 1.94%.
The time course of the effects of 70mgkg-' BW12C on
the RTP of RIF-1 tumours and a range of normal tissues are
shown in Figure 2. The top left panel shows data for intra-
muscular leg tumour and for muscle taken from the contra-
lateral leg, indicating that there is a reduction in tumour
RTP with a nadir of 84% at 1 h after drug administration.
This value is significantly less than control (P = 0.001). How-
ever it is matched by a similar reduction in muscle RTP to
86% at 1 h (P = 0.002, compared with control). There is
evidence that the tumour RTP remains depressed at 6 h after
treatment, while the muscle RTP has returned to control
values by 2 h after treatment. The top right panel shows data
for flank tumours and for skin from the contralateral leg.
BW12C causes a significant reduction in RTP for flank
tumours with the nadir also occurring at 1 h after treatment
when RTP is reduced to 68% ofcontrol (P = 10-4, compared
with control). However in the flank tumour the reduction
lasts longer, with RTP at 78% of control at 2 h (P = 0.002)
compared with control) and there is no corresponding
decrease in RTP of skin, the 'upstream' normal tissue. In
contrast, there is a rise in skin RTP to a maximum of 117%
of control 2 h after BW12C administration (0.1 >P>0.05 at
1 h; p<0.001 at 2 h). The reduction in RTP in flank tumours
is larger than for leg tumours in the same animals, e.g. at 1 h
flank tumour RTP is 68% ofcontrol compared with 84% for
leg tumours (P= 0.008) and also at 2 h the flank RTP of
78% is lower than the RTP for leg tumours (P = 0.002)
The effects of 70 mgkg-' BW12C on the RTP of other
normal tissues are shown in the lower two panels. Kidney,
spleen and lung and show qualitatively the same response,
although with marked differences in magnitude of change.
There is a significant increase in RTP from 30 min after
treatment, with a peak typically at 1 h and the increase still
significant 2 h after treatment, but there is a return to normal
values by 6 h. The largest increase was seen in spleen, where
RTP at 1 h was almost doubled to 173% of control, while
peak RTP for kidney was 157% of control at 30 min and for
lung was 128% of control at 1 h. All these increases are
highly significant (at 1 h and 2 h after treatment P = 10-4 for
all three tissues; at 30 min after treatment P= 10-4 for
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Figure 2 The time course of the effect of 70 mg kg-' BW12C on the relative tissue perfusion of RIF-I tumours and a range of
normal tissues in C3H mice. The data are pooled from either two or three experiments, typically with 9-12 mice per point for each
experiment. Points are mean values and bars show± 2 s.e. of the mean. (A) RIF-I leg tumour; (A) contralateral leg muscle; (V)
RIF-I flank tumour; (V) flank skin; (U) spleen; (0) kidney; (0) lung; (0) liver. Bars show± 2 s.e. Note that the scales on the
abscissae vary.
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kidney, P = 0.004 for spleen and P = 10-3 for lung). In
contrast in liver there was no significant increase in RTP in
the first hour after treatment, but at 2 h and 6 h there were
reductions to 85% (P = 0.02) and 79% (P = 0.01) respec-
tively.
Data to show the dose-response of these relative perfusion
effects are presented in Figure 3. This experiment was carried
out with flank tumours because the effect of BW12C on RTP
in flank tumours is larger than in leg tumours (see above).
Further experiments (not shown) have indicated that the
effect of BW12C in reducing tumour RTP is greater in larger
tumours, therefore the dose-response was investigated in
larger tumours of 450-550 mm3 in size. The data show (top
panel) that the threshold dose for reduction in tumour
RTP lies between 55 and 70 mgkg-'. RTP was reduced to
58% of control by 70mgkg-' (P= 10-4 compared with
control), a somewhat larger reduction than was seen in the
250-450 mm3 tumours (Figure 2), as expected. In kidney, the
increase in RTP was evident at both 55 and 70 mgkg-', with
RTP values of 143% and 142% respectively (P<0.005) but
the increase at 40mgkg-' to 121% of control was not
significant (P = 0.115). In spleen, all doses tested resulted in a
significant increase in RTP; values were 172%, 168% and
158% at 40, 55 and 70 mg kg-' respectively. No change from
control was observed in liver at the time chosen for this
assay, which is in agreement with the findings presented in
Figure 2. In lung however, as in kidney, there were signi-
ficant increases in RTP following 55 and 70 mgkg', with
RTP values of 129% and 136% respectively (P = 0.007 and
P = 0.003 respectively) but at 40 mg kg-' there was no
change from control. These normal tissue data show good
agreement with the data presented in Figure 2 for the same
BW12C dose and time of assay. The data as a whole indicate
that perturbations in normal tissue perfusion occur at lower
BW12C doses than do reductions in tumour perfusion in
these animals.
RIF-1 tumours both intramuscularly in the leg and intrader-
mally in the flank is very similar to that originally reported
by Brown et al. (1980). For both tumour sites there is close
agreement between to Do values noted in this study for
air-breathing animals and those in the original report: Do
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Effect ofBW12C on renalfunction
The effect of 70 mgkg-' BW12C on renal function was
assayed by the ability of the mouse to clear 5"CrEDTA from
the plasma. BW12C was given either together with EDTA or
30 min before EDTA. The parameters of the clearance curves
measured are presented in Table II and show that when
BW12C was given simultaneously with EDTA the rate of
clearance was slightly reduced by a factor (± 2 s.e.) of
1.26 ± 0.27. When EDTA was given 30 min after BW12C, at
which time the perturbation of kidney RTP was maximal,
there was no change in clearance rate. There was no change
in intercept of the curve for either administration schedule. A
further experiment was carried out investigating the effect of
BW12C on the clearance of "25I iodohippurate given 30min
after BW12C (data not shown) and, as for EDTA clearance,
no effect was seen.
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The pattern of radiosensitivity observed in this study for
Table I Theeffect of70mgkg-' BW12C on51CrEDTA clearance by
C3H mice
Slope
(±2 s.e.)a Intercept
Treatment x 100min-' (±2s.e.)a
Experiment A Control 5.31 6.57
(simultaneous (PBS) (4.57-6.05) (4.93-8.74)
BW12C and 70 mg kg- 4.22 7.00
EDTA) BW12C (3.52-4.92) (5.33-9.21)
Experiment B Control 6.04 8.17
(BW12C 30 min (PBS) (5.65-6.43) (7.13-9.36)
before EDTA) 70mgkg-' 6.38 8.24
BW12C (5.54-7.22) (6.00-9.68)
aClearance curve parameters were calculated from datafor 5-60 min
after EDTA injection.
240-
200
160-
120-
80^
40.
u
Lung
I
.. ..
30 40 50 60 70 80
BW12C dose (mg kg-1)
Figure 3 Data for a single experiment to investigate the dose-
dependence of the effects of BW12C on the relative tissue
perfusion of RIF-I intradermal flank tumours and a range of
normal tissues in C3H mice. Tumours used in this experiment
were from 450-550mm3 in size. RTP was assayed 1 h after
administration of BW12C. The stippled box indicates the range
of ±2 s.e. of the mean of the control values. 9-15 mice were
used for each point.
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(± 2 s.e.) for leg tumours was 2.03 (1.87-2.22) (Table I)
compared with 1.87 (1.60-2.23) (Brown et al., 1980) and for
flank tumours was 3.06 (2.36-4.34) (TableI) compared with
3.57 (2.60-5.64) (Brown et al., 1980). The BW12C-induced
increase in hypoxic fraction by a factor of 5.0 (2.3-11.3) for
the leg tumour (Table I) is consistent with our previous
observation of increases in survival by factors of 7.0
(5.0-9.0) assayed immediately and 3.8 (1.8-5.8) assayed 24 h
after irradiation for this tumour grown in the leg following a
radiation dose of 13 Gy (Honess et al., 1991b). The increase
in hypoxic fraction observed in the flank, a factor of 5.9
(1.9-18.2) (Table I) was very similar to that seen in the leg,
although since the initial hypoxic fraction was substantially
higher, the ultimate effect was to bring the degree of hypoxia
much closer to the anoxic state than was the case for the leg
tumour.
In the KHT tumour, BW12C increased the hypoxic frac-
tion in subcutaneous tumours from 16 (15- 18)% to 69
(62-77)%, i.e. by a factor of 4.2 (3.7-4.9). This effect is
comparable with that reported for KHT (Adams et al., 1989)
and Lewis lung (Adams et al., 1986) where BW12C increased
the hypoxic fraction from around 10% to 'close to' 100%. In
KHT intramuscular leg tumours we found that the increase
in hypoxic fraction was by a factor of 3.8 (2.8-5.3), again
very simliar to that in flanks, but this was inadequate to
bring to the level of hypoxia close to anoxic levels because
the initial hypoxic fraction was low. The hypoxic fraction for
the KHT tumour in the leg, 0.96 (0.80-1.14)% (TableI), was
notably lower than the 10% to 30% reported by other
laboratories (Siemann et al., 1978; Siemann & Macler, 1986;
Siemann & Keng, 1987), but it has been shown to increase
from 10% for 300-400 mg tumours to nearly 40% for
600-700 mg tumours (Hill, 1980). In the present study,
tumour size was particularly carefully controlled in these
experiments, using only tumours between 8.5 and 9.0 mm
mean diameter. It therefore seems likely that this rather low
hypoxic fraction observed in small intramuscular tumours is
attributable to the size of the tumours used, rather than to
differences in the tumour as used in different laboratories,
although the latter cannot be ruled out. The main conclusion
from the radiosensitivity studies was therefore that the in-
crease in hypoxic fraction was very similar, irrespective of the
type of tumours or its initial hypoxic fraction.
Prolonged hypoxia and/or reduced pH thermosensitise cells
in vitro (Hahn, 1974; Gerweck et al., 1979; Overgaard &
Bichel, 1977; Overgaard & Neilsen, 1980); however since
hypoxia typically results in decreased pH, it can be difficult
to determine the relative contributions of these interdepen-
dent factors to the ultimate toxic effect, particularly in vivo.
Acute hypoxia induced by inhibition of blood flow has also
been shown to potentiate thermal damage in two mouse
tumours (Horsman et al., 1989, Honess et al., 1991a). These
observations form the rationale for testing BW12C as a
potentiator of thermal killing in vivo. We have previously
demonstrated that the drug does not thermosensitise cells in
vitro (Honess, unpublished observations) and have also
shown that BW12C does not thermosensitise the RIF-1
tumour in the leg (Honess et al., 1989). However in this
tumour the hypoxic fraction is only increased to 1.5% by
BW12C (Table I). Clearly a tumour with a higher hypoxic
fraction would be better system in which to test the hypo-
thesis that BW12C may thermosensitise tumours, and the
KHT tumour was selected on the basis of published data on
its hypoxic fraction (see above). Leg tumour size was very
carefully controlled within the same limits for both the
thermosensitivity and radiosensitivity experiments, and these
limits were determined by the requirements of the hyperther-
mia system in order to ensure uniformity oftemperature. The
radiosensitivity data showed that the hypoxic fraction of the
KHT leg tumours was increased to around 4% by BW12C,
which was significantly higher than the hypoxic fraction of
1.5% for BW12C-treated RIF-1 in the leg, but far from full
radiobiological hypoxia. The data presented in the Results
section show that BW12C did not increase the thermal
damage produced by heat at temperatures from 43°C to
44°C. The small but measurable growth delay caused by
BW12C alone is at first sight in contrast to the absence of
cell killing by this dose of drug seen in the cell survival
studies. However, the drug did cause marked reduction in
blood flow (Figure 2) and hence deprivation of nutrition for
a period sufficient to check the growth of this rapidly grow-
ing tumour. In studies with hydralazine, using this tumour
system in this site, we have previously shown that growth
delay is closely related to duration of inhibition of blood flow
in addition to its dependence on cell killing (Honess et al.,
1991a). We conclude from the present data that the degree of
hypoxia induced by BW12C was inadequate to alter the
thermal response of the tumour. We were unable to investi-
gate the effect of heat on the tumour in the flank as the
hyperthermia system is designed only for the treatment of leg
tumours.
The comparative data on the effects of BW12C on relative
perfusion of RIF-1 tumours grown in the leg and flank
(Figure 2) confirm the preliminary report (Honess et al.,
1989) that perfusion is reduced. The data strongly suggest
that the reduction in perfusion contributes to the increase in
hypoxic fraction demonstrated to Figure 1 and Table I. The
time-course of the perfusion effects is such that perfusion
approaches its nadir during irradiation, which starts 30 min
after drug administration and continues for e.g. approxi-
mately 30min for 20Gy. We have previously shown that
maximum radioprotection of the RIF-1 tumour occurs when
radiation is started around 30min after BW12C administra-
tion, whereas the maximum haemoglobin modification is
observed 5 min after giving BW12C and this modification
decays with a half-life of about 1.25 h (Honess et al., 1991b).
The development of radioprotection therefore appears to
correlate rather better with the time-course of the perfusion
changes than with the haemoglobin modification. The data
are consistent with radioprotective hypoxia initially (5 min
after giving the drug) being primarily due to altered blood
chemistry, then as the haemoglobin alteration decays (1 h
after the drug) the effect of blood flow reduction becomes
relatively more important in maintaining hypoxia. By 2 h
after the drug, when blood flow has normalised and only
25% of the blood is modified, all radioprotection is lost.
The present data show that the reduction in perfusion in
the leg tumours appears to be secondary to a reduction in
perfusion of the muscle, the tissue 'feeding' the tumour, while
for the intradermal flank tumours the reduction is not depen-
dent on the perfusion of the skin. The reduction in muscle
perfusion was not significant in the preliminary experiments
(Honess et al., 1989), where absolute values for per cent
injected activity per gram were pooled rather than per cent of
mean control values and where there was greater variation in
the reproducibility of control values than in the present series
of experiments; this probably obscured the changes in
muscle. The reason for the difference in response between
intramuscular and intradermal tumours and their respective
upstream tissues is not clear. However, the proportional
changes in perfusion are broadly similar in both sites, with a
larger reduction in the flank tumours. This is consistent with
the larger increase in hypoxic fraction measured for flank
than for leg tumours (Table I) although there is no evidence
for a significant difference between the increases in flank and
leg.
The time course for change in relative perfusion after
BW12C in the remaining normal tissues measured was
somewhat similar in that a peak at either 30 min or 1 h was
followed by a drop at 2 h. However, in kidney, spleen and
lung this peak represented an increase in relative perfusion
followed by return to normal values, whereas in liver the
peak did not form a significant increase, but the subsequent
fall constituted a significant decrease from control values
(Figure 2). The rises observed may either reflect actual in-
creases in absolute blood flow, or possibly may indicate a
decrease in cardiac output at around 1 h. Relative tissue
perfusion is a measure of absolute blood flow as a proportion
of cardiac output. Hence RTP must inevitably rise when
cardiac output falls but absolute blood flow remainsBW12C: HYPOXIA AND BLOOD FLOW 721
unchanged. Similarly a reduction in cardiac output by the
same proportion as a reduction in blood flow will cause no
change in RTP, but a reduction in blood flow by a greater
proportion than a reduction in cardiac output will be
measured as a decrease in RTP. The similarity of pattern of
RTP changes in kidney, spleen, lung and liver suggested that
the changes in RTP might be due to a drop in cardiac output
with a nadir at 1 h after BW12C and recovery commencing
by 2 h. It is not currently feasible to measure cardiac output
in unanaesthetised mice, so a direct measurement was not
possible. Functional assays of the effects of BW12C on these
four organs were considered, and we chose to examine the
effects of BW12C on renal clearance. The data presented in
Table II shows that 30 min after BW12C, the time at which
RTP was maximal, there was no effect on EDTA or 125i-
iodohippurate clearance, while immediately after giving the
drug there was a very small decrease in EDTA clearance rate,
by a factor (± 2 s.e.) of 1.26 ± 0.27. EDTA clearance is used
as an assay for glomerular filtration rate and iodohippurate
clearance as an assay for effective renal plasma flow (Sweny
et al., 1989). These experiments showed that kidney function
was hardly altered by BW12C, and a possible inference is
that the RTP measurements may not indicate an increase in
absolute kidney flow but a decrease in cardiac output. The
RTP data are compatible with this hypothesis, but there is no
clear evidence to support it. Nonetheless, if it is true, since
any change in cardiac output is a constant in the determina-
tion of RTP in all tissues measured, the absolute reductions
in flow in tissues where RTP dropped must have been larger
than the measured reductions in RTP i.e. the reductions in
tumour RTP would be underestimates of the changes in
absolute tumour blood flow.
In summary, BW12C induces a comparable increase in
hypoxic fraction in both the RIF-I and KHT tumours,
whether these tumours are grown intramuscularly in the leg
(with a low hypoxic fraction) or intradermally or sub-
cutaneously in the flank (with a hypoxic fraction 15 to
17-fold higher). The blood flow studies indicate that a reduc-
tion in tumour perfusion is likely to be an important factor
in this increase in hypoxic fraction. It is not clear from these
studies how much of the radioprotection is attributable to
the reduction in perfusion and how much is due to changes
in oxygen release by alteration of blood chemistry by
BW12C.
We are very grateful to Ms Angela Prime for expert technical
assistance.
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